Lynne Anne Murray is an accomplished inventor based in King of Prussia, PA (US). He has made significant contributions to the field of medical treatments, particularly focusing on autoimmune and hypersensitive disorders. With a total of 2 patents, his work is paving the way for new therapeutic approaches.

Latest Patents

Murray's latest patents include innovative treatment methods for autoimmune disorders. The first patent provides methods and compositions for expanding T regulatory cells ex vivo or in vivo using one or more serum amyloid P (SAP) agonists. These methods are particularly useful in treating autoimmune diseases and preventing foreign graft rejection. The second patent addresses treatment methods for hypersensitive disorders. This invention describes a new mechanistic protein-based therapeutic approach for treating allergic airway diseases, which often involve detrimental side effects from current standard care options. The surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic effect in treating hypersensitive disorders is a significant advancement in this area.

Career Highlights

Lynne Anne Murray is currently associated with Promedior, Inc., where he continues to develop and refine his innovative treatment methods. His work is characterized by a commitment to improving patient outcomes through scientific research and development.

Conclusion

Lynne Anne Murray's contributions to the field of medical innovation are noteworthy, particularly in the treatment of autoimmune and hypersensitive disorders. His patents reflect a dedication to advancing therapeutic options and improving the quality of life for patients.

This text is generated by artificial intelligence and may not be accurate.